Showing 715 results
-
Media Release /- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be…
-
Media Release /The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living…
-
Media Release /
-
Media Release /
-
Media Release /- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
-
Media Release /
-
Media Release /Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…
-
Media Release /
-
Media Release /
-
Media Release /- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
